carvedilol has been researched along with Cirrhosis in 20 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether beta-blocker dose influences cardiac collagen turnover and the effects of spironolactone on cardiac collagen turnover in patients with heart failure." | 9.12 | Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure. ( Camp, JR; Cavallari, LH; Groo, VL; Momary, KM; Stamos, TD; Viana, MA, 2007) |
| " • Carvedilol reduced biventricular TGFβ1-CTGF signaling, fibrosis, and apoptosis." | 7.81 | Carvedilol improves biventricular fibrosis and function in experimental pulmonary hypertension. ( Breitling, S; Friedberg, MK; Honjo, O; Kato, H; Kuebler, WM; Okumura, K; Sun, M, 2015) |
| "To investigate the effects of carvedilol and metoprolol on cardiac fibrosis in rats with experimental myocardial infarction (MI)." | 7.74 | [Effects of carvedilol and metoprolol on cardiac fibrosis in rats with experimental myocardial infarction]. ( Chen, H; Guo, CY; Li, HW; Li, ZZ; Shen, LH; Sun, T; Tang, CS, 2008) |
| "Carvedilol (20 mg/kg, bid) or vehicle was given to rats surviving a myocardial infarction (MI) 24 h (n = 409)." | 7.71 | Long-term effects of carvedilol on left ventricular function, remodeling, and expression of cardiac cytokines after large myocardial infarction in the rat. ( Adam, A; Liu, P; Parker, TG; Rouleau, JL; Sia, YT; Tsoporis, JN, 2002) |
| "Carvedilol was administered intraperitoneally to 8 week-old TO2 hamsters for 21 weeks at a dose of 11 mg/kg/day." | 5.33 | Carvedilol prevents myocardial fibrosis in hamsters. ( Ishii, T; Nanjo, S; Togane, Y; Yamazaki, J; Yoshikawa, K, 2006) |
| "To determine whether beta-blocker dose influences cardiac collagen turnover and the effects of spironolactone on cardiac collagen turnover in patients with heart failure." | 5.12 | Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure. ( Camp, JR; Cavallari, LH; Groo, VL; Momary, KM; Stamos, TD; Viana, MA, 2007) |
| " • Carvedilol reduced biventricular TGFβ1-CTGF signaling, fibrosis, and apoptosis." | 3.81 | Carvedilol improves biventricular fibrosis and function in experimental pulmonary hypertension. ( Breitling, S; Friedberg, MK; Honjo, O; Kato, H; Kuebler, WM; Okumura, K; Sun, M, 2015) |
| "High-dose carvedilol alleviated LV remodelling and diastolic dysfunction following SVR accompanying with reduction in myocardial fibrosis." | 3.76 | Carvedilol may alleviate late cardiac remodelling following surgical ventricular restoration. ( Ikeda, T; Komeda, M; Marui, A; Muranaka, H; Nishina, T; Tsukashita, M; Wang, J; Yoshikawa, E, 2010) |
| "To investigate the effects of carvedilol and metoprolol on cardiac fibrosis in rats with experimental myocardial infarction (MI)." | 3.74 | [Effects of carvedilol and metoprolol on cardiac fibrosis in rats with experimental myocardial infarction]. ( Chen, H; Guo, CY; Li, HW; Li, ZZ; Shen, LH; Sun, T; Tang, CS, 2008) |
| "Carvedilol (20 mg/kg, bid) or vehicle was given to rats surviving a myocardial infarction (MI) 24 h (n = 409)." | 3.71 | Long-term effects of carvedilol on left ventricular function, remodeling, and expression of cardiac cytokines after large myocardial infarction in the rat. ( Adam, A; Liu, P; Parker, TG; Rouleau, JL; Sia, YT; Tsoporis, JN, 2002) |
| " The cardioprotective properties of carvedilol, a vasodilating beta-adrenoceptor-blocking agent, were studied in a rat model of dilated cardiomyopathy after autoimmune myocarditis." | 3.71 | Effects of carvedilol on cardiac function and cardiac adrenergic neuronal damage in rats with dilated cardiomyopathy. ( Aizawa, Y; Ashino, H; Fuse, K; Kodama, M; Nakazawa, M; Takahashi, T; Tanabe, N; Tazawa, S; Wahed, MI; Watanabe, K, 2002) |
| "Carvedilol appears to be a potentially viable option for treating portal hypertension." | 2.42 | Evaluation of carvedilol for the treatment of portal hypertension. ( Hemstreet, BA, 2004) |
| "Ascites is associated with a high risk of death." | 1.72 | Incidence of, Risk Factors for, and Outcomes After Ascites in a Population-Based Cohort of Older Americans. ( Mazumder, N; Parikh, ND; Tapper, EB; Zhao, Z, 2022) |
| "Carvedilol was adiministered for 4 weeks starting at week 13." | 1.56 | Carvedilol Diminishes Cardiac Remodeling Induced by High-Fructose/High-Fat Diet in Mice via Enhancing Cardiac β-Arrestin2 Signaling. ( Ibrahim, IAAE; Ibrahim, WS; Mahmoud, AAA; Mahmoud, MF, 2020) |
| "Treatment with carvedilol or amlodipine completely prevented left ventricular collagen deposition and morphometric alterations in aorta." | 1.46 | Effects of carvedilol or amlodipine on target organ damage in L-NAME hypertensive rats: their relationship with blood pressure variability. ( Berg, G; Bertera, FM; Carranza, A; Chiappetta, DA; Del Mauro, JS; Donato, M; Fernandez Machulsky, N; Gelpi, RJ; González, GE; Gorzalczany, SB; Höcht, C; Morales, C; Morettón, MA; Prince, PD; Taira, CA, 2017) |
| "Carvedilol was administered intraperitoneally to 8 week-old TO2 hamsters for 21 weeks at a dose of 11 mg/kg/day." | 1.33 | Carvedilol prevents myocardial fibrosis in hamsters. ( Ishii, T; Nanjo, S; Togane, Y; Yamazaki, J; Yoshikawa, K, 2006) |
| "2." | 1.31 | Renoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGF beta expression. ( Barone, F; Brooks, DP; Campbell, WG; Contino, LC; Gygielko, E; Laping, NJ; Nelson, AH; Olson, BA; Wong, VY, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (50.00) | 29.6817 |
| 2010's | 8 (40.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tapper, EB | 1 |
| Zhao, Z | 1 |
| Mazumder, N | 1 |
| Parikh, ND | 1 |
| Adachi, M | 1 |
| Watanabe, M | 1 |
| Kurata, Y | 1 |
| Inoue, Y | 1 |
| Notsu, T | 1 |
| Yamamoto, K | 2 |
| Horie, H | 1 |
| Tanno, S | 1 |
| Morita, M | 1 |
| Miake, J | 1 |
| Hamada, T | 1 |
| Kuwabara, M | 1 |
| Nakasone, N | 1 |
| Ninomiya, H | 1 |
| Tsuneto, M | 1 |
| Shirayoshi, Y | 1 |
| Yoshida, A | 1 |
| Nishimura, M | 1 |
| Hisatome, I | 1 |
| Ibrahim, WS | 1 |
| Ibrahim, IAAE | 1 |
| Mahmoud, MF | 1 |
| Mahmoud, AAA | 1 |
| Del Mauro, JS | 1 |
| Prince, PD | 1 |
| Donato, M | 1 |
| Fernandez Machulsky, N | 1 |
| Morettón, MA | 1 |
| González, GE | 1 |
| Bertera, FM | 1 |
| Carranza, A | 1 |
| Gorzalczany, SB | 1 |
| Chiappetta, DA | 1 |
| Berg, G | 1 |
| Morales, C | 1 |
| Gelpi, RJ | 1 |
| Taira, CA | 1 |
| Höcht, C | 1 |
| Zhu, JN | 1 |
| Chen, R | 1 |
| Fu, YH | 1 |
| Lin, QX | 1 |
| Huang, S | 1 |
| Guo, LL | 1 |
| Zhang, MZ | 1 |
| Deng, CY | 1 |
| Zou, X | 1 |
| Zhong, SL | 1 |
| Yang, M | 1 |
| Zhuang, J | 1 |
| Yu, XY | 1 |
| Shan, ZX | 1 |
| Okumura, K | 1 |
| Kato, H | 1 |
| Honjo, O | 1 |
| Breitling, S | 1 |
| Kuebler, WM | 1 |
| Sun, M | 1 |
| Friedberg, MK | 1 |
| Chen, YL | 2 |
| Chung, SY | 1 |
| Chai, HT | 1 |
| Chen, CH | 1 |
| Liu, CF | 1 |
| Huang, TH | 1 |
| Zhen, YY | 1 |
| Sung, PH | 1 |
| Sun, CK | 1 |
| Chua, S | 1 |
| Lu, HI | 1 |
| Lee, FY | 1 |
| Sheu, JJ | 1 |
| Yip, HK | 1 |
| Wang, K | 1 |
| Lu, D | 1 |
| Zhang, B | 1 |
| Wang, S | 1 |
| Liu, Q | 1 |
| Zhang, Q | 1 |
| Geng, J | 1 |
| Shan, Q | 1 |
| Sun, T | 1 |
| Shen, LH | 1 |
| Chen, H | 1 |
| Li, HW | 1 |
| Guo, CY | 1 |
| Li, ZZ | 1 |
| Tang, CS | 1 |
| Yoshikawa, E | 1 |
| Marui, A | 1 |
| Tsukashita, M | 1 |
| Nishina, T | 1 |
| Wang, J | 1 |
| Muranaka, H | 1 |
| Ikeda, T | 1 |
| Komeda, M | 1 |
| Elnakish, MT | 1 |
| Hassona, MD | 1 |
| Alhaj, MA | 1 |
| Moldovan, L | 1 |
| Janssen, PM | 1 |
| Khan, M | 1 |
| Hassanain, HH | 1 |
| Hemstreet, BA | 1 |
| Watanabe, K | 2 |
| Yaoita, H | 1 |
| Ogawa, K | 1 |
| Oikawa, M | 1 |
| Maehara, K | 1 |
| Maruyama, Y | 1 |
| Nanjo, S | 1 |
| Yamazaki, J | 1 |
| Yoshikawa, K | 1 |
| Ishii, T | 1 |
| Togane, Y | 1 |
| Tylicki, L | 1 |
| Biedunkiewicz, B | 1 |
| Chamienia, A | 1 |
| Wojnarowski, K | 1 |
| Zdrojewski, Z | 1 |
| Aleksandrowicz, E | 1 |
| Lysiak-Szydlowska, W | 1 |
| Rutkowski, B | 1 |
| Cavallari, LH | 1 |
| Momary, KM | 1 |
| Groo, VL | 1 |
| Viana, MA | 1 |
| Camp, JR | 1 |
| Stamos, TD | 1 |
| Wong, VY | 1 |
| Laping, NJ | 1 |
| Nelson, AH | 1 |
| Contino, LC | 1 |
| Olson, BA | 1 |
| Gygielko, E | 1 |
| Campbell, WG | 1 |
| Barone, F | 1 |
| Brooks, DP | 1 |
| Briest, W | 1 |
| Hölzl, A | 1 |
| Rassler, B | 1 |
| Deten, A | 1 |
| Leicht, M | 1 |
| Baba, HA | 1 |
| Zimmer, HG | 1 |
| Sia, YT | 1 |
| Parker, TG | 1 |
| Tsoporis, JN | 1 |
| Liu, P | 1 |
| Adam, A | 1 |
| Rouleau, JL | 1 |
| Takahashi, T | 1 |
| Nakazawa, M | 1 |
| Wahed, MI | 1 |
| Fuse, K | 1 |
| Tanabe, N | 1 |
| Kodama, M | 1 |
| Aizawa, Y | 1 |
| Ashino, H | 1 |
| Tazawa, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Renal Transplant Injury and the Renin-Angiotensin System in Kids (RETASK)[NCT03317925] | 29 participants (Actual) | Observational | 2014-07-16 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for carvedilol and Cirrhosis
| Article | Year |
|---|---|
Evaluation of carvedilol for the treatment of portal hypertension.
Topics: Adrenergic Antagonists; Carbazoles; Carvedilol; Esophageal and Gastric Varices; Fibrosis; Humans; Hy | 2004 |
2 trials available for carvedilol and Cirrhosis
| Article | Year |
|---|---|
Renal allograft protection with angiotensin II type 1 receptor antagonists.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Carbazoles; Carvedilol; Cross-Over Studi | 2007 |
Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Carbazoles; Carvedilol; Diuretics; Dose-Response | 2007 |
17 other studies available for carvedilol and Cirrhosis
| Article | Year |
|---|---|
Incidence of, Risk Factors for, and Outcomes After Ascites in a Population-Based Cohort of Older Americans.
Topics: Aged; Anticoagulants; Antiviral Agents; Ascites; Atorvastatin; Carvedilol; Diuretics; Fibrosis; Huma | 2022 |
β-Adrenergic Blocker, Carvedilol, Abolishes Ameliorating Actions of Adipose-Derived Stem Cell Sheets on Cardiac Dysfunction and Remodeling After Myocardial Infarction.
Topics: Adrenergic beta-Antagonists; Animals; Carvedilol; Cell Hypoxia; Cells, Cultured; Disease Models, Ani | 2019 |
Carvedilol Diminishes Cardiac Remodeling Induced by High-Fructose/High-Fat Diet in Mice via Enhancing Cardiac β-Arrestin2 Signaling.
Topics: Animals; beta-Arrestin 2; Cardiomegaly; Carvedilol; Cytokines; Diet, High-Fat; Dietary Sugars; Disea | 2020 |
Effects of carvedilol or amlodipine on target organ damage in L-NAME hypertensive rats: their relationship with blood pressure variability.
Topics: Amlodipine; Animals; Antihypertensive Agents; Aorta; Biomarkers; Blood Pressure; Blood Pressure Dete | 2017 |
Smad3 inactivation and MiR-29b upregulation mediate the effect of carvedilol on attenuating the acute myocardium infarction-induced myocardial fibrosis in rat.
Topics: Animals; Carbazoles; Cardiotonic Agents; Carvedilol; Down-Regulation; Fibroblasts; Fibrosis; Heart; | 2013 |
Carvedilol improves biventricular fibrosis and function in experimental pulmonary hypertension.
Topics: Animals; Antihypertensive Agents; Carbazoles; Carvedilol; Connective Tissue Growth Factor; Fibrosis; | 2015 |
Early Administration of Carvedilol Protected against Doxorubicin-Induced Cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Animals; Antibiotics, Antineoplastic; Biomarkers; Carbazoles; Cardiomyo | 2015 |
Renal Denervation Attenuates Multi-Organ Fibrosis and Improves Vascular Remodeling in Rats with Transverse Aortic Constriction Induced Cardiomyopathy.
Topics: Alanine Transaminase; Angiotensin II; Animals; Aorta; Blood Pressure; Carbazoles; Cardiomegaly; Card | 2016 |
[Effects of carvedilol and metoprolol on cardiac fibrosis in rats with experimental myocardial infarction].
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Collagen; Disease Models, Animal; Fibr | 2008 |
Carvedilol may alleviate late cardiac remodelling following surgical ventricular restoration.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Cardiac Catheterization; Carvedilol; Drug Evaluati | 2010 |
Rac-induced left ventricular dilation in thyroxin-treated ZmRacD transgenic mice: role of cardiomyocyte apoptosis and myocardial fibrosis.
Topics: Animals; Apoptosis; Blotting, Western; Carbazoles; Cardiomegaly; Cardiomyopathies; Carvedilol; Echoc | 2012 |
Attenuated cardioprotection by ischemic preconditioning in coronary stenosed heart and its restoration by carvedilol.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Coronary Stenosis; Drug Evaluation, Pr | 2006 |
Carvedilol prevents myocardial fibrosis in hamsters.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Cricetinae; Disease Models, Animal; Ec | 2006 |
Renoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGF beta expression.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Carbazoles; Carvedilol; Collagen Type I; Dieta | 2001 |
Cardiac remodeling after long term norepinephrine treatment in rats.
Topics: Adrenergic Antagonists; Analysis of Variance; Animals; Blotting, Western; Calcium Channel Blockers; | 2001 |
Long-term effects of carvedilol on left ventricular function, remodeling, and expression of cardiac cytokines after large myocardial infarction in the rat.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Cytokines; Fibrosis; Gas Chromatograph | 2002 |
Effects of carvedilol on cardiac function and cardiac adrenergic neuronal damage in rats with dilated cardiomyopathy.
Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Adrenergic Fibers; Animals; Autoimmune Diseases; | 2002 |